Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,891.00
Bid: 2,879.00
Ask: 2,881.00
Change: 49.00 (1.72%)
Spread: 2.00 (0.069%)
Open: 2,853.00
High: 2,891.00
Low: 2,846.00
Prev. Close: 2,842.00
III Live PriceLast checked at -
3i Group is an Investment Trust

To provide its shareholders with quoted access to private equity and infrastructure returns, its main focus is on making quoted and unquoted equity and/ or debt investments in businesses and funds in Europe, Asia and the Americas.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FY2018 Q3 performance update

1 Feb 2018 07:00

RNS Number : 5537D
3i Group PLC
01 February 2018
 

1 February 2018

 

3i Group plc

FY2018 Q3 performance update

 

A positive quarter and on track to deliver another year of strong growth

 

· NAV per share of 701 pence and total return of 19.4% for the nine months to 31 December 2017

 

· Private Equity cash realisations of £389 million in the nine months to 31 December 2017. In addition, announced the c.€307 million divestment of ATESTEO in December 2017

 

· Completed two add-on investments in Cirtec Medical and Ponroy Santé, taking year to date Private Equity cash investment to £585 million

 

· Strong performance from 3i Infrastructure plc ("3iN") as its share price increased by 7% in the quarter following the announcement of its divestments of Elenia and Anglian Water Group

 

· Invested £167 million in our first US infrastructure investment, Smarte Carte, in November 2017 and disposed of our residual Debt Management investments, generating proceeds of £127 million

 

Simon Borrows, Chief Executive, commented:

 

"This was another positive quarter for 3i. Action's expansion continued with the opening of 244 new stores in 2017, including six pilot stores in Poland. We announced the realisation of one of our 2013-2016 investments, ATESTEO, at an excellent money multiple of 4.4x. In addition, we completed our first US Infrastructure investment and two important further investments in Private Equity, reinforcing our strategy of building platform investments. We enter the final quarter of our financial year confident that our investment portfolio will deliver another year of strong growth."

 

 

Private Equity

 

Portfolio performance

The Private Equity portfolio had a good quarter. Action performed strongly again in 2017, with sales up by 28% and 244 new store openings in the year. In 2017, Action also commenced a significant investment programme across stores, supply chain, distribution, IT and human resources in order to meet the scale and breadth of its expansion programme. Action opened two distribution centres in France and Germany during the year. In the second half, it also instigated further investment and a change in its logistics service provider at the Moissy distribution centre in order to overcome performance issues in store delivery in France. Action now has 1,100 stores and, in just five years, the French store network is generating more sales per week than the network in the Netherlands.

 

Action will be publishing its audited results for 2017 in March. Its Board has initiated a new refinancing and, subject to market conditions, plans to make another distribution to its shareholders before 31 March 2018.

 

The majority of the portfolio continued to perform well with notable value growth increases from Basic-Fit, Scandlines, Audley Travel and AES. Christ, our German jewellery business, suffered from weak footfall during the final quarter, in line with the rest of the German high street.

 

Private Equity investments

In November 2017, we made a £69 million further investment in Cirtec Medical to support its transformative acquisition of Vascotube Gmbh ("Vascotube") a provider of nitinol tubing used in minimally invasive implantable medical devices. We also invested a further £10 million in Ponroy Santé to enable it to acquire ERSA Group ("Aragan"), a designer and distributor of premium pharmaceutical food supplements.

 

Private Equity realisations

We generated total cash proceeds in the quarter of £39 million, principally from the £30 million received from ATESTEO's refinancing in November 2017.

 

Realisation proceeds

£m

Full realisations

Hobbs

7

Partial realisations

Other

2

Refinancings

ATESTEO

30

Total Q3 2018 cash proceeds

39

H1 2018 cash proceeds

350

Total cash proceeds as at 31 December 2017

389

 

In December 2017, we announced the realisation of ATESTEO for proceeds of €307 million, subject to completion adjustments. This transaction is expected to complete before 31 March 2018 and will generate a 4.4x euro money multiple. At 31 December 2017, ATESTEO was held on an imminent sales basis and valued at £277 million, an uplift of 52% compared to its value at 30 September 2017.

 

 

Infrastructure

 

Our European Infrastructure team had a very successful quarter, including advising 3iN on its divestments of Elenia and Anglian Water Group, which will generate estimated proceeds on divestment of £725 million and £395 million respectively for 3iN. The team also advised 3iN on the buyout of Barings' investment in Wireless Infrastructure Group, which completed in early January 2018. 3iN's share price performed strongly in the quarter, closing up 7% at 208 pence, generating unrealised value growth of £47 million for 3i.

 

Our US Infrastructure team completed its $226 million / £167 million investment in Smarte Carte and is working on an interesting pipeline of investment opportunities.

 

 

Other assets

 

In the quarter, we completed the disposal of the residual Debt Management investments, generating proceeds of £127 million (30 September 2017 book value: £127 million).

 

 

Total return and NAV position

 

We recognised a £31 million gain on foreign exchange in the quarter, as the euro strengthened against sterling. Based on the balance sheet at 31 December 2017, a 1% movement in the euro and US dollar would result in a total return movement of £43 million and £9 million respectively. The diluted NAV per share increased to 701 pence (30 September 2017: 652 pence) or 693 pence ex-dividend after deducting the 8p per share interim dividend.

 

 

Balance sheet

 

Top 10 investments by value at 31 December 2017*

Valuation

Valuation

Valuation

Valuation

Sep-17

Dec-17

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

2,009

2,312

Valued using run-rate EBITDA to 31 December 2017

3i Infrastructure plc

Quoted

GBP

670

717

ATESTEO

Imminent sales

EUR

182

277

Announced sale in the quarter

Basic-Fit

Quoted

EUR

218

236

Q Holding

Earnings

USD

243

231

Weener Plastic

Earnings

EUR

218

227

Audley Travel

Earnings

GBP

208

222

Hans Anders

Earnings

EUR

195

204

Cirtec Medical

Earnings

USD

99

167

Further investment of £69 million

Smarte Carte

Price of recent investment

USD

-

167

New investment in the quarter

 

The 10 investments in this table comprise 66% (30 September 2017: 61%) of the total Proprietary Capital portfolio value of £7,184 million (30 September 2017: £6,584 million).

* This table does not include one investment which has been excluded for commercial reasons.

Liquidity

The Group's balance sheet remains well funded. Net debt increased to £137 million, following the investments in Smarte Carte and Cirtec Medical in the quarter, and gearing increased to 2%. Liquidity remained strong at £790 million. The 8 pence FY2018 interim dividend (£77 million) was paid on 10 January 2018. We anticipate strong cash inflows over the next few months.

 

 

- ENDS -

 

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 31 December 2017 in this update have been calculated at a currency exchange rate of 1.1248:£1 and $1.3519:£1 respectively. At 31 December 2017, 64% of the Group's net assets were in euro and 12% were in US dollar.

2.

At 31 December 2017, 3i had 969.8 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 16.0x based on its run-rate earnings to 31 December 2017, the closest period end to 3i's.

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

Kathryn van der Kroft

Communications DirectorTel: 020 7975 3021

 

 

 

About 3i Group

 

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com.

 

All statements in this performance update relate to the three month period ended 31 December 2017, unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2017 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBBMPTMBTJBTP
Date   Source Headline
1st May 20248:58 amRNSDirector/PDMR Shareholding
30th Apr 20244:34 pmRNSTotal Voting Rights
2nd Apr 20248:01 amRNSPortfolio Update
28th Mar 20241:02 pmRNSTotal Voting Rights
28th Mar 20241:00 pmRNSDirector/PDMR Shareholding
21st Mar 20241:53 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSAction Capital Markets Seminar & portfolio update
1st Mar 202410:11 amRNSDirector/PDMR Shareholding
29th Feb 20244:21 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNS3i Group plc - Q3 performance update
31st Jan 20244:17 pmRNSTotal Voting Rights
31st Jan 20244:14 pmRNSDirector/PDMR Shareholding
4th Jan 20243:36 pmRNSTotal Voting Rights
4th Jan 20243:35 pmRNSDirector/PDMR Shareholding
3rd Jan 202412:00 pmRNSPortfolio Update
8th Dec 20231:11 pmRNSBlock listing Interim Review
30th Nov 20234:55 pmRNSTotal Voting Rights
30th Nov 20234:51 pmRNSDirector/PDMR Shareholding
23rd Nov 202311:11 amRNSDirector Declaration
20th Nov 20239:13 amRNSDirector Declaration
9th Nov 20232:29 pmRNSDirector/PDMR Shareholding
9th Nov 202311:49 amRNSDoc re. Half Yearly Report 2023
9th Nov 20237:00 amRNSHalf-year Report
31st Oct 20233:29 pmRNSTotal Voting Rights
31st Oct 20233:27 pmRNSDirector/PDMR Shareholding
2nd Oct 202312:58 pmRNSDirector/PDMR Shareholding
2nd Oct 202310:36 amRNSPortfolio Update
28th Sep 20231:35 pmRNSDirector/PDMR Shareholding
20th Sep 20237:00 amRNSUpdate on portfolio and Capital Markets Seminar
12th Sep 202310:43 amRNSDirector/PDMR Shareholding
4th Sep 202310:41 amRNSDirector/PDMR Shareholding
31st Aug 20233:56 pmRNSTotal Voting Rights
31st Aug 20233:52 pmRNSDirector/PDMR Shareholding
1st Aug 202311:40 amRNSDirector/PDMR Shareholding
31st Jul 20234:31 pmRNSTotal Voting Rights
31st Jul 20234:27 pmRNSDirector/PDMR Shareholding
20th Jul 20237:00 amRNSFY2024 Q1 performance update
3rd Jul 202310:25 amRNSPortfolio Update
30th Jun 20233:43 pmRNSTotal Voting Rights
30th Jun 20233:37 pmRNSDirector/PDMR Shareholding
30th Jun 202311:01 amRNSDirector/PDMR Shareholding
29th Jun 20235:00 pmRNSDirectorate Change
29th Jun 20233:46 pmRNSDirector/PDMR Shareholding
29th Jun 20233:31 pmRNSDoc re. AGM Resolutions
29th Jun 20233:30 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM and portfolio update
28th Jun 20232:34 pmRNSDirector/PDMR Shareholding
12th Jun 20232:33 pmRNSPublication of a Prospectus
9th Jun 20239:44 amRNSBlock listing Interim Review
8th Jun 20232:51 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.